Trilin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trilin

The following overview defines Trilin by its composition, pharmacological identity, and general role, providing a foundation for understanding the medication.

Property Description
Active Ingredient Amitriptyline
Form Film-coated tablet (Oral)
Pharmacological Class Tricyclic Antidepressant (TCA)
Origin Synthetic (Dibenzocycloheptene derivative)
General Purpose Mood stabilization and relief of certain chronic pain types

Trilin: The Drug Class and Identity

Trilin is a prescription-only medication defined by its active chemical substance, Amitriptyline, which places it within the Tricyclic Antidepressant (TCA) pharmacological class. This classification is derived from the molecule's unique three-ring chemical structure. TCAs represent a foundational and robust class of psychotropic medications historically utilized for their effects on the central nervous system. The distinct chemical properties of Amitriptyline, which include potent anticholinergic and sedative effects, set it apart from newer antidepressant agents, a difference that has been widely observed in clinical settings for decades. The active ingredient is a widely studied TCA.


Composition and General Therapeutic Role

The core therapeutic component of Trilin is the synthetic compound Amitriptyline Hydrochloride, which is a single-ingredient product commonly presented as a film-coated tablet for oral administration. The compound belongs to the dibenzocycloheptene chemical class. Its pharmacological identity is unique because it is metabolized in the body into the secondary amine Nortriptyline, which is also pharmacologically active, sustaining the medicine's effect. This dual active action contributes to its use not only for mood stabilization but also for managing symptoms associated with persistent, chronic pain related to the nervous system. The medicine's effect is achieved by modulating the reuptake of key neurotransmitters, such as norepinephrine and serotonin.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Trilin?

Possible Side Effects and Safety Information for Trilin

All medicines have potential side effects, and Trilin's safety profile is documented by regulatory health authorities based on clinical data and post-marketing reports.

Adverse Reaction Summary

Adverse reactions are classified primarily by frequency and the organ system affected.

System-Organ Class (SOC) Common Adverse Reactions (may affect up to 1 in 10 people)
Nervous System Sleepiness, Dizziness, Headache, Confusion, Tremors, Speech disorder
Gastrointestinal Constipation, Dryness in mouth, Nausea
Cardiovascular Orthostatic hypotension (sudden drop in blood pressure upon standing), Palpitations
General Fatigue, Weight gain
Psychiatric/Sexual Decreased libido, Aggressive behavior

Serious Adverse Reactions and Safety Considerations

Serious Adverse Drug Reactions (SADRs) are events that may be life-threatening, result in death, require hospitalization, cause disability, or result in a birth defect. These events, regardless of whether they are expected, must be reported to central health authorities for continuous monitoring of the drug's safety.

Clinically Significant Risks: The use of Trilin is associated with the potential for increased suicidal ideation or behavioral changes, particularly when treatment is initiated or the dose is adjusted, and this risk may be more pronounced in young adults (under 25 years old). The drug may also cause severe skin disorders or issues with vision, and the risk of serotonin syndrome exists when taken with certain other medications.

Population-Specific Safety: Caution is advised in patients with pre-existing liver or kidney disease, where dose adjustment may be necessary. Use during the last trimester of pregnancy may result in withdrawal-like symptoms in the newborn, and the drug is generally considered potentially unsafe during breastfeeding, as small amounts may pass into breast milk.

Overdose and Emergency Response

Overdose and when to seek help

The active ingredient in Trilin, Amitriptyline, belongs to a class of medications for which overdose is considered potentially life-threatening according to regulatory documents. Symptoms typically become apparent within a few hours, though delayed effects can occur.

Classification Documented Overdose Presentations
Physiological Systems Affected Central Nervous System (CNS), Cardiovascular System, Peripheral Autonomic Nervous System
Life-Threatening Outcomes Cardiac dysrhythmias (e.g., ventricular fibrillation), QRS complex prolongation, severe hypotension, seizures, and coma

Regulatory authorities mandate that if an overdose is suspected, immediate medical attention must be sought right away by calling the local emergency number or Poison Control. Overdose is serious enough that patients are almost always admitted to the hospital for monitoring due to the risk of sudden deterioration.

Initial emergency procedures include obtaining a 12-lead EKG and continuous cardiac monitoring. Treatment is officially defined as symptomatic and supportive, as no specific antidote is known. Measures described in regulatory-aligned guidelines include the use of sodium bicarbonate to manage cardiac conduction abnormalities.

Therapeutic Uses of Trilin

Quick Facts: Trilin Uses

  • Depression: An option for the management of depressive disorder.
  • Neuropathic Pain: May offer relief for pain related to nerve damage.
  • Headache/Migraine: Can be used in the management of certain types of headaches, including migraine.

What Trilin Treats: Main Uses and Benefits

Trilin is a medication prescribed to manage several conditions. Its primary use is in the management of depression, where it may help to support mood and reduce symptoms related to depressive disorder. The therapy may also be a management option for patients experiencing certain types of neuropathic pain, which is pain resulting from nerve damage.

In addition to its uses in mood and nerve pain, Trilin may be recommended as part of a treatment plan for migraine or certain tension-type headaches in adults, helping to reduce the frequency of these occurrences.

Clinical evidence suggests that this medication is part of a therapeutic approach that may help individuals achieve a better sense of well-being and improved daily function across these indications.

Eligibility and Restrictions for Use

Who Can and Cannot Use Trilin? (Amitriptyline)

Official regulatory documents strictly define the population eligibility for Trilin (Amitriptyline) based on age, physiological status, and coexisting medical conditions.

Contraindications (Must Not Use)

Trilin is contraindicated and must not be used by patients with:

  • Known hypersensitivity to the medicine or its components.
  • Use of Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.
  • An acute recovery phase following a myocardial infarction (heart attack).
  • Severe liver disease or existing heart conduction defects (e.g., heart block).

Age and Special Population Restrictions

Population Group Eligibility Status Restriction Type
Adults (General Use) Approved Standard labeled conditions.
Children under 6 years Prohibited Contraindicated for all uses.
Adolescents (General Use) Not Recommended Safety and efficacy not fully established.
Older Adults (65+) Conditional Use Requires caution; lower starting dose often necessary.

Use is also restricted and requires caution for pregnant women (Category C), nursing mothers, and individuals with a history of seizures, angle-closure glaucoma, or non-severe impaired liver function, as detailed in official prescribing information. Use for Nocturnal Enuresis is specifically approved for children aged 6 years and above.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interactions documented in official government regulatory documents (e.g., FDA Prescribing Information and EMA Summary of Product Characteristics). It does not include advice, dosing instructions, or therapeutic use information.


Contraindicated and Restricted Combinations

Trilin is strictly prohibited for use with certain classes of medicines due to the potential for serious outcomes. Co-administration is forbidden with Monoamine Oxidase Inhibitors (MAOIs) intended to treat psychiatric disorders. Similarly, linezolid and intravenous methylene blue are restricted from co-administration. A washout period of 14 days is required after stopping an MAOI before starting Trilin, and 21 days is required after stopping Trilin before starting an MAOI.


Exposure-Modifying Substances

Interactions involving substances that affect drug levels (exposure) are classified by regulatory authorities as clinically significant and require management.

Interacting Substance Category Constraint / Requirement
Strong Inhibitors of CYP2D6 Mandatory dose reduction of Trilin by one-half.
Strong Inducers of CYP Enzymes Dose increase of Trilin may be considered if co-administered for more than 14 days.

Co-administration with other serotonergic agents (medicines that increase the effects of serotonin) may necessitate immediate discontinuation of one or both therapies due to potential additive effects.

Mechanism of Action

Trilin functions as a non-selective inhibitor of neuronal monoamine reuptake within the central nervous system. The compound primarily binds to and blocks the presynaptic transporters for both serotonin (5-HT) and norepinephrine (NE). This competitive inhibition prevents the reabsorption of these neurotransmitters from the synaptic cleft back into the presynaptic neuron, thereby increasing the concentration and duration of action of both 5-HT and NE at their respective postsynaptic receptor sites. The resulting molecular pathway is a sustained enhancement of monoaminergic neurotransmission.

Downstream cascades include modulation of various intracellular signaling pathways linked to G-protein-coupled receptors and tyrosine kinase receptors, leading to adaptive changes in receptor sensitivity and expression over time. System-level physiological consequences involve a generalized modulation of CNS function, including altered autonomic nervous system output and modification of various brain circuits regulating arousal and pain processing.

Dosage and Administration Information

How to Use Trilin

The use of Trilin (Amitriptyline) is governed by specific procedural guidelines. The medicine is intended for oral administration as a tablet and can be taken with or without food. Tablets should be swallowed whole; the score line on some forms is only to facilitate swallowing and not for dividing into equal doses.

Dosing is highly dependent on the condition being addressed. For adult outpatient use, the maximum daily dose is 150 mg. Use for neuropathic pain generally starts lower, around 10 mg to 25 mg daily, with a usual maintenance range of 25 mg to 75 mg. The daily dose is often taken once at bedtime or in divided doses.

Treatment initiation requires a gradual dose increase (titration) over several days or weeks. Population-specific adjustments include lower starting doses for older adults (10 mg to 25 mg daily) and specific dosing (10 mg to 50 mg daily) only for children aged 6 years and above for nocturnal enuresis. If a dose is missed, standard protocols advise skipping the missed dose and taking the next scheduled dose at the usual time; doses must not be doubled. Treatment cessation must involve a gradual dose reduction (tapering) over several weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trilin


Evidence for Major Depressive Disorder (MDD)

The research into Trilin's use for MDD is extensive, relying on a large volume of Randomized Controlled Trials (RCTs) and subsequent meta-analyses that span many decades. This evidence was studied for adult populations in research exploring how symptoms change over time. Studies examined changes in symptom intensity and the rates at which individuals met a defined change in symptom measurements (known as clinical response).

Early studies reported measurements of symptom score changes when compared to placebo in the adult population. However, a significant portion of the evidence is historical, and there is limited information for long-term outcomes regarding the continuation of measured symptom changes or the rate of return of symptoms. This means that long-term effects are not fully established by the highest-quality, modern research standards.


Evidence for Neuropathic Pain

Trilin was studied for pain management in conditions where symptoms may vary in intensity and are often linked to nerve damage (neuropathy). Research relied on Randomized Controlled Trials (RCTs), comparing the medicine to placebo, primarily in adults with conditions like diabetic peripheral neuropathy and postherpetic neuralgia.

Studies explored short-term outcomes describing episodic or acute changes in pain intensity over observation periods of several weeks to a few months. A key limitation noted is that the follow-up durations were limited in many primary RCTs, meaning the continuation of observed changes in pain measurements over many months or years is not fully established.


Evidence Gaps and Areas of Uncertainty

Another significant gap is that long-term effects are not fully established, as most trials did not extend beyond the short or intermediate term needed to assess acute change. For some uses, such as chronic pain management, comparative evidence is lacking against the full range of newer treatments that are now available. These limitations mean that the findings describe group patterns, not personal outcomes, and that research provides context but not individual predictions.

Key Studies & References

  1. AMITRIPTYLINE HYDROCHLORIDE tablet, film coated - FDA Drug Label (via DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Trilin (FAQ)


Q: How long does it usually take for a person to notice the effects of Trilin?

Studies and official information indicate that while the medicine begins working on brain chemicals quickly, the full described therapeutic effects may not appear until approximately 10 to 14 days after starting the treatment. The process of gradually adjusting the dose is typically needed before the effects are fully realized.


Q: Can Trilin be taken by older adults or is it more suitable for younger people?

Official guidelines note that older adults, typically those 65 years and older, are often started on lower doses than the general adult population. This requirement reflects the potential for increased sensitivity to the medicine and other physiological factors in older adults. The medicine is generally contraindicated for use in children under 6 years of age.


Q: What happens if a person misses a dose of Trilin?

Regulatory instructions consistently advise that if a person misses a dose, the official instructions describe skipping that missed dose entirely and simply continuing with the next scheduled dose at the usual time. Official guidelines advise that doses should not be doubled to compensate for the missed one.


Q: Are there any official warnings about stopping Trilin suddenly?

Yes, official instructions advise that treatment cessation should involve a gradual dose reduction over several weeks, known as tapering. Abrupt discontinuation of the medicine, especially after prolonged use, is associated with the potential for physical and psychological discontinuation (or withdrawal-like) symptoms.


Q: Does Trilin interact with over-the-counter cold and flu medications?

Official warnings exist against combining Trilin with certain ingredients often found in common cold and flu products. This includes cough suppressants like dextromethorphan and decongestants that contain sympathomimetic agents (such as phenylephrine). Regulatory warnings indicate that these combinations carry an increased potential for side effects, such as serotonin syndrome or adverse cardiovascular effects.


Q: Is there a known possibility of sexual side effects like reduced libido with Trilin?

Yes, official documents describe decreased libido (sex drive) as a common adverse reaction that may occur. Other potential effects reported include difficulties with sexual performance, such as delayed orgasm or erectile difficulties.


Q: Does taking Trilin make people feel 'emotionally numb' or 'flat'?

Official regulatory documents do not specifically list the terms 'emotional numbness' or 'flatness.' However, adverse reactions listed include confusion and psychotic symptoms in some patients. This suggests the medicine can influence a person’s emotional and cognitive state.


Q: Do the side effects of Trilin typically lessen or go away over time?

Regulatory documents do not guarantee that side effects will resolve. However, reports indicate that some adverse reactions, particularly those that appear early in treatment, such as sleepiness or dry mouth, may become less noticeable over the first few weeks of use as the body adjusts to the medicine.


Q: Can Trilin cause low blood pressure (hypotension) when standing up?

Yes, official documents list orthostatic hypotension as a common adverse reaction. This is the medical term for a sudden drop in blood pressure that can cause feelings of dizziness or faintness when a person moves quickly from a sitting or lying position to a standing position.


Q: Can Trilin cause 'brain fog' or difficulty with concentration?

Official documents list confusion as a common adverse reaction, which is especially noted in older adults. Related common side effects like drowsiness and headache may also be experienced, and these effects can affect concentration.


Q: Is Trilin considered a Monoamine Oxidase Inhibitor (MAOI)?

No, Trilin is not classified as a Monoamine Oxidase Inhibitor (MAOI). It belongs to the Tricyclic Antidepressant (TCA) class. Official prescribing documents explicitly state that combining Trilin with MAOIs is forbidden.


Q: Can Trilin cause any vision changes, like blurred vision or dry eyes?

Official documents list potential adverse reactions involving vision, including blurred vision and, in rare cases, changes in eye pressure. The medicine is also associated with dry mouth, and this anticholinergic effect can often lead to other dryness symptoms like dry eyes.


Q: Does Trilin affect appetite, causing either an increase or a loss of interest in food?

Yes, official documents note that changes in appetite are a possible adverse reaction associated with the use of Trilin. This change can sometimes lead to weight gain, which is also listed as a common side effect.


Q: Can Trilin affect sleep patterns, such as causing insomnia or excessive drowsiness?

Official adverse reaction lists include both extremes: drowsiness (sleepiness) is common, which is why the medicine is frequently administered in the evening. However, some patients may also experience difficulty falling asleep or staying asleep (insomnia), as well as nightmares.


Q: What is the difference between Trilin tablets and Trilin liquid/syrup forms?

Trilin is available as a solid film-coated tablet and in an oral solution (liquid/syrup) form. The oral solution form is typically available for patients who may have difficulty swallowing tablets.


Q: Is there any research evidence on the use of Trilin during pregnancy or breastfeeding?

Official documents classify Trilin in Pregnancy Category C, which suggests potential risks cannot be ruled out. The drug is known to pass into breast milk in small amounts. Use during the last trimester of pregnancy may also be associated with temporary withdrawal-like symptoms in newborns.


Q: Is there a need for blood tests or regular monitoring while taking Trilin?

While regulatory labels do not mandate general blood tests for all patients, they note caution is needed for those with pre-existing liver or kidney disease. Regulatory documents suggest that patients and their caretakers should observe for any significant changes in mood or behavior, particularly when initiating treatment.


Q: Is it possible for Trilin to interact with herbal remedies like St. John's Wort?

Yes, official guidance from some authorities explicitly warns against taking the herbal remedy St. John’s wort with Trilin, stating that this combination can increase the risk of side effects. Information on other herbal remedies is generally not established in official documents.


Q: Can Trilin affect blood sugar levels or is it safe for people with diabetes?

Official precautions note that Trilin has been reported to cause both elevation and lowering of blood sugar levels. It is noted that people who have conditions affecting blood sugar, such as diabetes, should be cautious of this potential effect.


Q: What are the common differences in side effects between low and high doses of Trilin?

The official guidance involves a gradual dose increase (titration) which is intended to help minimize adverse effects. This implies that the risk and intensity of common side effects, such as sleepiness and dry mouth, are generally greater and more frequent at higher doses.


Q: Can taking Trilin cause an increased sensitivity to sunlight or skin rashes?

Yes, Trilin is documented to potentially cause an increased sensitivity to the sun (photosensitivity), which means a person may sunburn more easily. Additionally, the drug has been associated with the potential for severe skin rashes, which are considered serious adverse symptoms.


Q: Is it possible for Trilin to cause urinary retention or difficulty passing urine?

Yes, difficulty urinating and urinary retention (inability to empty the bladder completely) are listed in official adverse reaction documents as a possible side effect of Trilin. This is an anticholinergic effect and may be more common in older patients.

How should Trilin be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal procedures for Trilin (Amitriptyline) are governed by official regulatory standards to ensure product stability and safety. The medication must be stored at controlled room temperature, generally defined as between 20 C and 25 C. It is mandatory to protect the tablets from excessive heat and moisture.

Storage and Handling Constraints

The tablets should remain in their original container, which must be kept tightly closed. A critical safety requirement is that Trilin must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Trilin should be disposed of according to local requirements. Authorized drug take-back programs are the preferred disposal method. If a take-back program is unavailable, official guidelines permit mixing the medicine with an undesirable substance and sealing it in a bag before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trilin found in:

A-Z Index: